Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
537
datasets available to search
ShareScore release 0.9.0
Dataset results
537 results for “Pharmaceuticals”
Baltimore Ecosystem Study polar organic contaminant integrative sampler data for pharmaceuticals and personal care products in core sites within Gwynns Falls watershed and reference sites.
An ongoing component of the Baltimore urban long-term ecological research (LTER) project (Baltimore Ecosystem Study, BES) is the use of the watershed approach and monitoring of stream water quality to evaluate the impacts of multiple chemical stressors on urban stream ecosystem functioning within Baltimore. The LTER research has focused on the Gwynns Falls watershed, which spans a gradient from highly urban, urban-residential, and suburban zones. In addition, a forested watershed serves as a reference. The long-term sampling network includes four longitudinal sampling sites along the Gwynns Falls mainstem, as well as several small (40-100 ha) watershed within or near the Gwynns Falls, providing data on water quality in different land use zones of the watersheds. Each study site is continuously monitored for discharge and is sampled weekly for water chemistry. Those data are available elsewhere on the BES website. We are interested in studying the presence and concentrations of pharmaceuticals and personal care products (PPCPs) within urban streams, and then linking these PPCPs with various stream ecosystem functions. To quantify the concentrations of PPCPs in streams, we deploy polar organic contaminant integrative samples (POCIS), which integrate all organic contaminants that pass by them in a stream over a set period of deployment. These POCIS allow us to integrate the total amount of PPCPs within a stream over a set period of time, and then to relate these concentrations with other ecosystem processes. We monitored PPCP concentration in four suburban to urban sites within the Gwynns Falls, as well as one exurban and one forested stream monitoring site. Each POCIS was deployed for two weeks at a stream monitoring site in March 2012. After completion of the sampling period, POCIS were removed from the streams and shipped on ice to the University of Nebraska for extraction and quantification of recovered compounds. This dataset includes all compounds extracted and q
Supplementary material 1 from: Sharmin S, Sohrab MH, Moni F, Afroz F, Rony SR, Akhter S (2020) Simple RP-HPLC method for Aceclofenac quantitative analysis in pharmaceutical tablets. Pharmacia 67(4): 383-391. https://doi.org/10.3897/pharmacia.67.e57981
Table S1. HPLC Analytical methods for simultaneous estimation of Aceclofenac with other constituents
Efficient removal of pharmaceuticals from water using graphene nanoplatelets as adsorbent
<p class="RSCB01ARTAbstract"><span>Recently, pharmaceutical pollutants in water emerge as global concern as they give threat to human health and environment. In this study, graphene nanoplatelets (GNPs) were used to efficiently remove antibiotics sulfamethoxazole (SMX) and analgesic acetaminophen (ACM) as pharmaceutical pollutants from water by adsorption process. GNPs; C750, C300, M15, and M5 were characterized by high-resolution transmission electron microscopy, Raman spectroscopy, X-Ray diffraction and Brunauer-Emmett-Teller. The effects of several parameters; viz., solution pH, adsorbent amount, initial concentration and contact time were studied. The parameters were optimized by batch adsorption process and the maximum removal efficiency for both pharmaceuticals were 99%. The adsorption kinetics and isotherms model were employed, and the experimental data were best analysed with pseudo-second kinetic and Langmuir isotherm with maximum adsorption capacity (Qm) of 210.08 mg g<sup>-1</sup> for sulfamethoxazole and 56.21 mg g<sup>-1</sup> for acetaminophen. Regeneration study were applied using different eluents; 5% ethanol-deionized water 0.005 M NaOH and HCl. GNP C300 were able to remove most of both pollutants from environmental water samples. Molecular docking was used to simulate the adsorption mechanism of GNP C300 towards sulfamethoxazole and acetaminophen with free binding energy of -7.54 kcal mol<sup>-1</sup> and -5.29 kcal mol<sup>-1</sup> respectively which revealed adsorption occurred spontaneously.</span></p>
Data from: Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices
Objectives: To develop and pilot a tool to measure and improve pharmaceutical companies' clinical trial data sharing policies and practices. Design: Cross sectional descriptive analysis. Setting: Large pharmaceutical companies with novel drugs approved by the US Food and Drug Administration in 2015. Data sources: Data sharing measures were adapted from 10 prominent data sharing guidelines from expert bodies and refined through a multi-stakeholder deliberative process engaging patients, industry, academics, regulators, and others. Data sharing practices and policies were assessed using data from ClinicalTrials.gov, Drugs@FDA, corporate websites, data sharing platforms and registries (eg, the Yale Open Data Access (YODA) Project and Clinical Study Data Request (CSDR)), and personal communication with drug companies. Main outcome measures: Company level, multicomponent measure of accessibility of participant level clinical trial data (eg, analysis ready dataset and metadata); drug and trial level measures of registration, results reporting, and publication; company level overall transparency rankings; and feasibility of the measures and ranking tool to improve company data sharing policies and practices. Results: Only 25% of large pharmaceutical companies fully met the data sharing measure. The median company data sharing score was 63% (interquartile range 58-85%). Given feedback and a chance to improve their policies to meet this measure, three companies made amendments, raising the percentage of companies in full compliance to 33% and the median company data sharing score to 80% (73-100%). The most common reasons companies did not initially satisfy the data sharing measure were failure to share data by the specified deadline (75%) and failure to report the number and outcome of their data requests. Across new drug applications, a median of 100% (interquartile range 91-100%) of trials in patients were registered, 65% (36-96%) reported results, 45% (30-84%) were published, and 95% (69-100%) were publicly available in some form by six months after FDA drug approval. When examining results on the drug level, less than half (42%) of reviewed drugs had results for all their new drug applications trials in patients publicly available in some form by six months after FDA approval. Conclusions: It was feasible to develop a tool to measure data sharing policies and practices among large companies and have an impact in improving company practices. Among large companies, 25% made participant level trial data accessible to external investigators for new drug approvals in accordance with the current study's measures; this proportion improved to 33% after applying the ranking tool. Other measures of trial transparency were higher. Some companies, however, have substantial room for improvement on transparency and data sharing of clinical trials.
Data from: Water-borne pharmaceuticals reduce phenotypic diversity and response capacity of natural phytoplankton communities
Chemical micropollutants occur worldwide in the environment at low concentrations and in complex mixtures, and how they affect the ecology of natural systems is still uncertain. Dynamics of natural communities are driven by the interaction between individual organisms and their growth environment, which is mediated by the organisms' expressed phenotypic traits. We tested whether exposure to a mixture of 12 pharmaceuticals and personal care products (PPCP) influences phenotypic trait diversity in lake phytoplankton communities and their ability to regulate biomass production to fit environmental changes (response capacity). We exposed natural phytoplankton assemblages to three mixture levels in permeable microcosms maintained at three depths in a eutrophic lake for one week, during which the environmental conditions were fluctuating. We studied individual-level traits, phenotypic diversity and community biomass. PPCP reduced individual-level trait variance and overall community phenotypic diversity, but maintained higher standing phytoplankton biomass compared to untreated controls. Estimated effect sizes of PPCP on traits and community properties were very large (partial Eta-squared > 0.15). The PPCP mixture antagonistically interacted with the natural environmental gradient in habitats offered by different depths and, at concentrations comparable to those in waste-water effluents, prevented communities from converging to the same phenotypic structure and total biomass of unexposed controls. We show that micropollutants can alter individual-level trait diversity of lake phytoplankton communities and therefore their capacity to respond to natural environmental gradients, potentially affecting aquatic ecosystem processes.
Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV) in Asian settings: the cross-sectional surveillance study -PEDA study
<p>This is the raw data for the PEDA study.</p>
Research database - Regulations, Manuals and Technical Standards Professional Career Pharmaceutical Sciences and Biochemistry
<p><span>This database contains information on Regulations, Manuals and Technical Standards of the Professional Career of Pharmaceutical Sciences and Biochemistry. Inca Garcilaso de la Vega University. Lima Peru</span></p> <p><span> </span></p>
Data from: Simultaneous determination of diosmin and hesperidin in combined pharmaceutical preparation by synchronous fluorescence spectrofluorimetric method
<p>Diosmin (DSM) and hesperidin (HSP) binary mixture was analyzed simultaneously by developing a sensitive, rapid, and simple synchronous spectrofluorimetric method. In methanol at ∆λ of 100 nm, the relative synchronous fluorescence intensities (RSFI) of both medications were measured. It was shown that these intensities were influenced by distinct experimental factors. The optimization and detailed study of these parameters were conducted. For DSM and HSP, respectively, the plots of synchronous fluorescence intensity-concentration were found to be rectilinear across the ranges of 0.5-5.0 µg/mL and 0.2-3.0 µg/mL. For DSM and HSP, respectively, 0.107 µg/mL and 0.048 µg/mL were the detection limits and 0.323 and 0.144 µg/mL were the limits of quantification. The method described in this study was effectively employed to estimate the quantities of both drugs present in commercially available mixed tablets. The results produced using this method were then compared favorably to results obtained using a different method for comparison.</p>
Responses Dataset of Healthcare Providers' KAP Regarding Halal Pharmaceuticals in Jordan Survey
Open the record for dataset details and reuse information.
Refining ligand poses in RNA/ligand complexes of pharmaceutical relevance: a perspective by QM/MM simulations and NMR measurements
<p>This directory contains files for the project:</p> <p>Title: Refining ligand poses in RNA/ligand complexes of pharmaceutical relevance: a perspective by QM/MM simulations and NMR measurements</p> <p>Authors: Gia Linh Hoang, Manuel Röck, Aldo Tancredi, Thomas Magauer, Davide Mandelli, Jörg B. Schulz, Sybille Krauss, Giulia Rossetti, Martin Tollinger, Paolo Carloni</p> <p>There are two folders containing input and parameter files of the classical MD simulations with GROMACS and QM/MM simulation with MiMiC, and an input file for NMR Chemical Shifts calculation with ORCA.</p>
Evaluating the potential of Digital Twin technology on pharmaceutical manufacturing efficiency in Ireland: An in-depth analysis of Machinery Validation
<p>The dissertation titled <strong>"Evaluating the Potential of Digital Twin Technology on Pharmaceutical Manufacturing Efficiency in Ireland: An In-depth Analysis of Machinery Validation"</strong> explores the transformative impact of Digital Twin (DT) technology within Ireland's pharmaceutical manufacturing sector. Conducted by MSc candidate Gayathri Gopakumar at Griffith College Dublin, the research focuses on how DT technology can enhance machinery validation processes, thereby improving operational efficiency and ensuring regulatory compliance.</p> <p>Employing a qualitative research methodology, the study includes semi-structured interviews with industry experts to gather insights into the current awareness, perceived benefits, and challenges associated with DT adoption in the pharmaceutical industry. The research aims to provide a comprehensive understanding of DT technology's role in machinery validation and its broader implications for manufacturing efficiency.</p> <p>This work contributes to the existing body of knowledge by offering a detailed analysis of DT technology's potential applications in pharmaceutical manufacturing, with a specific focus on the Irish context. It serves as a valuable resource for professionals and researchers interested in the integration of advanced digital technologies in the pharmaceutical sector.</p>
The German research-performing pharmaceutical industry on Twitter
<p>Science communication undergraduate student. </p>
Pharmaceutical Logistics Supply Chain: Challenges and Possible Solutions
<p>Explore the complexities of pharmaceutical supply chain management in this comprehensive article. Discover the challenges faced, such as regulatory compliance and counterfeit drugs, and delve into innovative solutions like blockchain technology and smart packaging. Learn how these advancements enhance efficiency, ensure product safety, and improve patient outcomes in the global pharmaceutical industry</p>
Impact of Generation Z on Pharmaceutical Marketing, Sales, and Compliance - Full Panel Discussion
<p>This video captures the full panel discussion on the impact of Generation Z on pharmaceutical marketing, sales, and compliance. The panel features insights from industry experts, marketing strategists, compliance officers, and Gen Z doctors, discussing the challenges and opportunities in engaging with this demographic. Key themes include digital engagement, value-driven marketing, ethical considerations, and the adoption of emerging technologies.</p>
Appendix for 'Current Trends of Digital Marketing in the Indian Pharmaceutical Industry'
<p>This appendix provides supplementary materials for the research paper titled <em>"Current Trends of Digital Marketing in the Indian Pharmaceutical Industry."</em> It includes detailed survey questions, statistical analyses, reliability and validity reports, and comparisons of digital marketing strategies between Indian and multinational pharmaceutical companies.</p>
Clinical Trial Transparency and Data-Sharing Among Bio-Pharmaceutical Companies and the Role of Company Size, Location, and Product Type: A Cross-Sectional Descriptive Analysis
<p><b>Objective</b>: To examine company characteristics associated with better transparency and to apply a tool used to measure and improve clinical trial transparency among large companies and drugs, to smaller companies and biologics.</p> <p><b>Design</b>: Cross-sectional descriptive analysis.</p> <p><b>Setting and participants. </b>Novel drugs and biologics FDA approved in 2016 and 2017, and their company sponsors.</p> <p>Using established Good Pharma Scorecard (GPS) measures, companies and products were evaluated on their clinical trial registration, results dissemination, and FDA Amendments Act (FDAAA) implementation; Companies were ranked using these measures and a multi-component data sharing measure. Associations between company transparency scores with company size (large vs non-large), location (US vs non-US), and sponsored product type (drug vs biologic) were also examined. 26% of products (16/62) had publicly available results for all clinical trials supporting their FDA approval and 67% (39/58) had public results for trials in patients by 6 months after their FDA approval; 58% (32/55) were FDAAA compliant. Large companies were significantly more transparent than non-large companies (overall median transparency score of 95% [IQR 91-100] vs 59% [IQR 41-70], p<0.001), attributable to higher FDAAA compliance (median of 100% [IQR 88-100] vs 57% [0-100], p=0.01) and better data sharing (median of 100% [IQR 80-100] vs 20% [IQR 20-40], p<0.01). No significant differences were observed by company location or product type. It was feasible to apply the GPS transparency measures and ranking tool to non-large companies and biologics. Large companies are significantly more transparent than non-large companies, driven by better data sharing procedures and implementation of FDAAA trial reporting requirements. Greater research transparency is needed, particularly among non-large companies, to maximize the benefits of research for patient care and scientific innovation. </p>
Green and sensitive spectrofluorimetric determination of two pharmaceutically important cephalosporin drugs in their dosage forms
<p>Using two green and sensitive spectrofluorimetric methods, we quantified two cephalosporins, cefepime (CFM) and cefazolin (CFZ), as raw and pharmaceutical formulations. The first method is based on the reaction between CFM and fluorescamine (borate buffer, pH 8), which yields a highly fluorescent product. After excitation at 384 nm, the fluorescent product emits light at 484 nm. At concentrations from 12 to 120 ng/mL, the relative fluorescence intensity/concentration curve was linear with a limit of quantification (LOQ) of 2.46 ng/mL. The second method relied on measuring the CFZ quenching action on acriflavine fluorescence through formation of an ion-associate complex using a Britton–Robinson buffer at pH 8. We measured acriflavine fluorescence at 505 nm after excitation at 265 nm. The fluorescence intensity decrease was CFZ-concentration dependent. Using this method, we quantified CFZ concentrations ranging from 1to 10 µg/mL with an LOQ of 0.48 µg/mL. We studied and optimized the factors influencing reaction product formation. Moreover, we adapted our methods to the investigation of the mentioned drugs as raw and pharmaceutical formulations with great results. We statistically validated our methods according to ICH guidelines. Our results were consistent with those obtained with the official HPLC methods.</p>
Data for: Can pharmaceutical pollution alter the spread of infectious disease? A case study using fluoxetine.
<p>Human activity is changing global environments at an unprecedented rate, imposing new ecological and evolutionary ramifications on wildlife dynamics, including host-parasite interactions. Here we investigate how an emerging concern of modern human activity, pharmaceutical pollution, influences the spread of disease in a population, using the water flea <em>Daphnia</em> <em>magna</em> and the bacterial pathogen <em>Pasteuria</em> <em>ramosa</em> as a model system. We found that exposure to different concentrations of fluoxetine—a widely prescribed psychoactive drug and widespread contaminant of aquatic ecosystems—affected the severity of disease experienced by an individual in a non-monotonic manner. The direction and magnitude of any effect, however, varied with both the infection outcome measured, as well as the genotype of the pathogen. In contrast, the characteristics of unexposed animals, and thus the growth and density of susceptible hosts, were robust to fluoxetine. Using our data to parameterise an epidemiology model, we show that fluoxetine is unlikely to lead to a net increase or decrease in the likelihood of an infectious disease outbreak, as measured by a pathogen's transmission rate or basic reproductive number. Instead, any given pathogen genotype may experience a two-fold change in likely fitness, but often in opposing directions. Our study demonstrates that changes in pharmaceutical pollution give rise to complex genotype-by-environment interactions in its influence on disease dynamics, with repercussions on pathogen genetic diversity and evolution.</p>
Dataset for estimating the impact of generic entry of pharmaceuticals in Australia
<p>Dataset used in our paper: The impact of generic entry of pharmaceuticals in Australia</p>
The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit
ClinicalTrials.gov study NCT02922140. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.